Effect of BG-12 on contrast-enhanced lesions in patients with relapsing-remitting multiple sclerosis: subgroup analyses from the phase 2b study

Kappos L., Gold R., Miller D. H., MacManus D. G., Havrdova E., Limmroth V., ...Daha Fazla

MULTIPLE SCLEROSIS JOURNAL, cilt.18, sa.3, ss.314-321, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 3
  • Basım Tarihi: 2012
  • Doi Numarası: 10.1177/1352458511421054
  • Dergi Adı: MULTIPLE SCLEROSIS JOURNAL
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.314-321
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: In a phase 2b study in patients with relapsing-remitting MS (RRMS), BG-12 240 mg three times daily significantly reduced the number of new gadolinium-enhanced (Gd+) lesions from weeks 12 to 24 (primary end point) by 69% compared with placebo.